文献速递瓣膜病与结构性心脏病

Sortilin通过诱导间质细胞异质性促进主动脉瓣纤维化与钙化

Sortilin enhances fibrosis and calcification in aortic valve disease by inducing interstitial cell heterogeneity.
PubMed 文献 · Eur Heart J · 2023-01-01

本研究在主动脉瓣损伤小鼠模型和人类原代瓣膜间质细胞中探索Sortilin(SORT1)在钙化性主动脉瓣病中的作用。Sortilin缺失减轻小鼠主动脉瓣纤维化、钙化和狭窄,并减少体外瓣膜间质细胞钙化。单细胞测序发现一种新的炎症性肌纤维母细胞-成骨性瓣膜间质细胞表型(IMO-VIC),Sortilin缺失可减少该表型。

要点

  • Sortilin缺失减轻小鼠主动脉瓣纤维化、钙化和狭窄
  • Sortilin介导人类瓣膜间质细胞向肌纤维母细胞样表型转化
  • 单细胞测序鉴定出IMO-VIC新表型,Sortilin缺失可减少其出现

核心结论

  • Sortilin通过介导瓣膜纤维化和钙化以及新鉴定的IMO-VIC表型促进钙化性主动脉瓣病。

研究设计与样本

  • 使用Sortilin缺陷的主动脉瓣导线损伤小鼠模型评估对狭窄、纤维化和钙化的影响。
  • 体外实验采用人类原代瓣膜间质细胞在成骨条件下培养7、14和21天,进行成像、蛋白质组学和转录组学分析包括单细胞RNA测序。

主要发现

  • Sortilin缺陷小鼠较同窝对照显示主动脉瓣纤维化、钙化和狭窄减轻。
  • 蛋白质研究确定Sortilin介导人类瓣膜间质细胞向肌纤维母细胞样表型转化。
  • Sortilin功能缺失减少体外瓣膜间质细胞钙化。
  • 单细胞RNA测序鉴定人类瓣膜间质细胞样本中12个差异表达细胞簇,检测到新型IMO-VIC表型,其SORT1、COL1A1、WNT5A、IL-6和血清淀粉样蛋白A1表达增加。
  • Sortilin缺陷的瓣膜间质细胞测序显示IMO-VIC表型减少。

临床怎么用

  • Sortilin可能作为治疗靶点,通过同时减少炎症、纤维化和钙化来抑制IMO-VIC出现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Calcific aortic valve disease (CAVD) is the most common valve disease, which consists of a chronic interplay of inflammation, fibrosis, and calcification. In this study, sortilin (SORT1) was identified as a novel key player in the pathophysiology of CAVD, and its role in the transformation of valvular interstitial cells (VICs) into pathological phenotypes is explored. METHODS AND RESULTS: An aortic valve (AV) wire injury (AVWI) mouse model with sortilin deficiency was used to determine the effects of sortilin on AV stenosis, fibrosis, and calcification. In vitro experiments employed human primary VICs cultured in osteogenic conditions for 7, 14, and 21 days; and processed for imaging, proteomics, and transcriptomics including single-cell RNA-sequencing (scRNA-seq). The AVWI mouse model showed reduced AV fibrosis, calcification, and stenosis in sortilin-deficient mice vs. littermate controls. Protein studies identified the transition of human VICs into a myofibroblast-like phenotype mediated by sortilin. Sortilin loss-of-function decreased in vitro VIC calcification. ScRNA-seq identified 12 differentially expressed cell clusters in human VIC samples, where a novel combined inflammatory myofibroblastic-osteogenic VIC (IMO-VIC) phenotype was detected with increased expression of SORT1, COL1A1, WNT5A, IL-6, and serum amyloid A1. VICs sequenced with sortilin deficiency showed decreased IMO-VIC phenotype. CONCLUSION: Sortilin promotes CAVD by mediating valvular fibrosis and calcification, and a newly identified phenotype (IMO-VIC). This is the first study to examine the role of sortilin in valvular calcification and it may render it a therapeutic target to inhibit IMO-VIC emergence by simultaneously reducing inflammation, fibrosis, and calcification, the three key pathological processes underlying CAVD.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Iqbal F, Schlotter F, Becker-Greene D, et al. Sortilin enhances fibrosis and calcification in aortic valve disease by inducing interstitial cell heterogeneity. Eur Heart J. 2023. PMID: 36660854. doi:10.1093/eurheartj/ehac818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。